TIDMGENI
RNS Number : 9734X
GENinCode PLC
02 May 2023
GENinCode Plc
("GENinCode" or the "Company")
NHS accelerates implementation of LIPID inCode (R) testing of
patients
suffering with hypercholesterolemia and familial
hypercholesterolemia
NHS earmarks budget to expand GENinCode's LIPID inCode(R)
polygenic testing to prevent Cardiovascular Disease
Oxford, UK. GENinCode Plc (AIM: GENI), the genetics company
focused on the prevention of cardiovascular disease, announces the
expansion of its collaboration with the Academic Health Science
Network for the North East and North Cumbria ("AHSN NENC") to use
the LIPID inCode(R) polygenic test in Primary Care for the
diagnosis of familial (inherited) hypercholesterolemia ("FH") with
available information to physicians for polygenic
hypercholesterolemia (high levels of cholesterol) and coronary
heart disease risk.
NHS funding to accelerate LIPID inCode(R) testing has been
earmarked to improve the diagnosis and treatment of FH to prevent
cardiovascular disease ("CVD"). Expanding access to genetic testing
for FH, which causes early onset of heart attacks (myocardial
infarction or "MI"), will enable the identification, earlier
diagnosis and treatment of patients at high genetic risk of a heart
attack. Improved detection of patients at genetic risk supports
better treatment and preventative care to avoid a heart attack. The
acceleration of LIPID inCode(R) testing will support the delivery
of the NHS 10 Year Plan to identify at least 25% of those
individuals suffering with FH by 2024 as part of the NHS genomics
programme. The NHS 10 Year Plan for FH is at the forefront of
cardiovascular clinical improvements to reduce CVD mortality in the
UK.
LIPID inCode(R) is the first commercial polygenic test to
prevent CVD to be implemented by the NHS. LIPID inCode(R) provides
a comprehensive diagnosis of FH and assesses an individuals
inherited genetic risk of hypercholesterolemia and coronary heart
disease. GENinCode will deliver LIPID inCode(R) using its
proprietary SITAB 'cloud based' system and datasets enabling a
rapid turnaround of test results (10-15 days) at reduced cost to
the NHS.
The NHS funding follows the positive results of the LIPID
inCode(R) NHS clinical study (1) and successful completion of the
AHSN NENC pilot. The NHS have now commenced LIPID inCode(R) testing
in the Darlington Primary Care Network (PCN) and community practice
representing over 100,000 patients in the North of England. The
collaboration will diagnose patients with genetic disorders giving
rise to high levels of cholesterol an important risk factor leading
to the development of CVD.
In the UK around 7.6m people live with heart and circulatory
disease, which causes 25% of all deaths annually. CVD can be
reduced by identifying and treating individuals at risk, and the
NHS 10 Year Plan (2019) sets out to address CVD prevention,
including identifying individuals with hypercholesterolemia and
particularly those with FH. FH is an inherited monogenic condition
which affects an individual's ability to regulate and remove
cholesterol from their blood. FH affects approximately 1 in 250
people in the UK population and globally.
Matthew Walls, CEO of GENinCode PLC said: "The collaboration
with the AHSN NENC continues to expand the use of LIPID inCode
testing to identify patients at high risk of heart disease
representing the largest cause of death in the UK and globally. We
are now extending implementation of LIPID inCode to other UK AHSN's
marking a further NHS milestone for the roll-out and adoption of
our leading polygenic test. We look forward to supporting the NHS
in reaching its long term goal to diagnose patients with
hypercholesterolemia and provide earlier risk assessment of CVD to
improve health outcomes."
Professor Julia Newton, Medical Director at AHSN NENC commented:
"We are delighted to accelerate the implementation of LIPID
inCode(R) for the diagnosis and treatment of hypercholesterolemia
and familial hypercholesterolemia. The added benefit of easy sample
collection, improved test turnaround times at a reduced costs to
the NHS, continues to help us deliver the Lipid inCode test in our
primary care practice and we welcome this approach to help us
deliver the NHS 10-Year plan to reduce the onset of cardiovascular
disease."
For more information visit www.genincode.com
Enquiries:
GENinCode Plc www.genincode.com or via Walbrook PR
Matthew Walls, CEO
Stifel Nicolaus Europe Limited (Nomad and Joint Broker) Tel: +44 (0)20 7710 7600
Alex Price / Ben Maddison / Richard Short
Cenkos Securities Plc (Joint Broker) Tel: +44 (0)20 7397 8900
Giles Balleny
Dale Bellis / Michael Johnson (Sales)
Walbrook PR Limited Tel: 020 7933 8780 or genincode@walbrookpr.com
Anna Dunphy / Phillip Marraige / Louis Ashe-Jepson
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk
assessment of cardiovascular disease. Cardiovascular disease is the
leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through
GENinCode S.L.U, and in the United States through GENinCode U.S.
Inc.
GENinCode predictive technology provides patients and physicians
with globally leading preventative care and treatment strategies.
GENinCode CE marked invitro-diagnostic molecular tests combine
clinical algorithms and bioinformatics to provide advanced patient
risk assessment to predict disease onset.
About Academic Health Science Network for the North East and
North Cumbria (AHSN NENC):
The AHSN NENC is focused on building and maintaining strong
relationships and partnerships which is fundamental to its success.
Member organisations and stakeholders include NHS, academia and
industry partners in the North East and North Cumbria.
By developing and maintaining strong relationships with members
and practitioners, the Network continually shares knowledge and
translates ideas into practice. The Network benefits from
harnessing the expertise and experience of clinical staff, for
example, to act as change agents to adopt and diffuse new practice
across organisations and support the research community to develop
knowledge.
To deliver against what is a broad remit, the Network works in
close collaboration with The AHSN Network across the UK as well as
with other national organisations, such as NIHR Clinical Research
Network . Other partnerships are developed where appropriate, for
example, with the third sector and with industry.
There are 15 Academic Health Science Networks ("AHSN") across
England, established by NHS England in 2013 to spread innovation at
pace and scale - thereby improving health and generating economic
growth. Each AHSN works across a distinct geography serving a
different population in each region. The AHSN NENC leads the
national AHSN programme to better identify FH in collaboration with
the Accelerated Access Collaborative (AAC) and the National
Institute for Health & Care Excellence (NICE).
About Cardiovascular Disease (CVD):
Heart and circulatory disease also known as Cardiovascular
disease (CVD) is the leading cause of death globally, taking an
estimated 17.9 million lives each year. CVD is a group of disorders
of the heart and blood vessels that include coronary heart disease,
cerebrovascular disease, rheumatic heart disease and other
conditions. More than four out of five CVD deaths are due to heart
attacks and strokes, and one third of these deaths occur
prematurely in people under 70 years of age.
The most important behavioural risk factors of heart disease and
stroke are unhealthy diet, physical inactivity, tobacco use and
harmful use of alcohol. The effects of behavioural risk factors may
show up in individuals as raised blood pressure, raised blood
glucose, raised blood lipids, and overweight and obesity. These
"intermediate risks factors" can be measured in primary care
facilities and indicate an increased risk of heart attack, stroke,
heart failure and other complications.
Identifying those at highest risk of CVDs and ensuring they
receive appropriate treatment can prevent premature deaths. Access
to noncommunicable disease medicines and basic health technologies
in all primary health care facilities is essential to ensure that
those in need receive treatment and counselling.
Cardiovascular disease, causes a quarter of all deaths in the UK
and is the largest cause of premature mortality in deprived areas
and is the single biggest area where the NHS can save lives over
the next 10 years. CVD is largely preventable, through lifestyle
changes and a combination of public health and NHS action on
smoking and tobacco addiction, obesity, tackling alcohol misuse and
food reformulation.
Early detection and treatment of CVD can help patients live
longer, healthier lives is set out in the NHS 10 Year Plan. Too
many people are still living with undetected, high-risk conditions
such as raised cholesterol, high blood pressure and atrial
fibrillation (AF). Globally, healthcare systems are making progress
on identification and diagnosis of high genetic risk individuals
and working towards people routinely knowing and understanding
their 'ABC' (AF, Blood pressure and Cholesterol risk). Replicating
this approach is now increasingly possible with advanced molecular
testing and digital technology.
Expanding access to genetic testing for Familial
Hypercholesterolemia (FH), which causes early heart attacks will
enable the diagnosis and treatment of those patients at genetic
risk of sudden cardiac death. The NHS set out in the 10 Year Plan
to identify at least 25% of those individuals suffering with FH by
2024 through the NHS genomics programme.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCNKDBKKBKDNPK
(END) Dow Jones Newswires
May 02, 2023 02:00 ET (06:00 GMT)
Genincode (LSE:GENI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Genincode (LSE:GENI)
Historical Stock Chart
From Jul 2023 to Jul 2024